Blood Research Group

HSCI research inspires startup

November 16, 2016

Startup Magenta Therapeutics licences technologies from Harvard, MGH, and Boston Children's that could transform treatment of blood diseases and immune disorders

Harvard University has completed a license agreement with Magenta Therapeutics, a new startup company launched in Cambridge, for a portfolio of technologies with the potential to transform blood stem cell transplants from a “treatment of last resort” into a safer, more efficient therapy for patients with blood diseases and immune …